This website uses cookies to ensure you get the best experience on our website. Privacy Policy

Contact
Login
Sign Up Free

Transformative Evidence
- mCRPC
- mHSPC
  - ARANOTE Trial
  - ARASENS Trial
- nmCRPC
  - ARAMIS Trial
- nmCSPC
  - EMBARK Trial
- PSMA PET Imaging
- Bladder Cancer
Centers of Excellence
- Urologic Oncology
  - Left Group
    - Health Policy
      - Health Policy
        Ruchika Talwar, MD
    - Bladder Cancer
    - Kidney Cancer
      - Advanced Kidney Cancer
        Pedro Barata, MD, MSc
    - Endourology
      - Endourology
        Jaime Landman, MD
  - Prostate Cancer
  - Disparities: Social Determinants of Health
    - Disparities: Social Determinants of Health
      Samuel L. Washington III, MD, MAS
  - Translational Prostate Cancer
    - Translational Science in Prostate Cancer
      Andrea Miyahira, Ph.D
    - Women in Science
      Andrea Miyahira, Ph.D
  - Upper Tract Urothelial Carcinoma
    - Upper Tract Urothelial Carcinoma
      Sam S. Chang, MD, MBA
  - TESTICULAR, PENILE & RARE GU MALIGNANCIES
    - Testicular Cancer
- Pelvic Health & Reconstruction
Videos
- Exclusives
- Urologic Oncology
- Pelvic Health & Reconstruction
  - Pelvic Health & Reconstruction
Trials in Progress
- Trials in Progress
  - Bladder Cancer
  - Kidney Cancer
    - RadiCal
    - SAMURAI
- Middle Side
  - Prostate Cancer
- Right Side
  - Prostate Cancer
Clinical Trials
- From the Editor
  - Search Clinical Trials
Articles
- Urology (benign and malignant)
- Pelvic Health
  - Pelvic Health & Reconstruction
Conference Coverage
- Recent Conferences
- All Conferences
  - View All
- Quick Takes
  - ESMO 2024
PCF

UroToday Home
Available Urotoday Newsletters - Site Registration Required

GU Onc Weekly

Value-Based Care and Reducing Prescription Drug Costs Sent on 18 December 2024 Receive via e-mail

Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer PrognosticationSent on 17 December 2024 Receive via e-mail

Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate CancerSent on 16 December 2024 Receive via e-mail

Bone Health in Advanced Prostate CancerSent on 14 December 2024 Receive via e-mail

Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting for Muscle-invasive Bladder Cancer Sent on 13 December 2024 Receive via e-mail

Practice-Changing Data in Metastatic Prostate Cancer Sent on 12 December 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 11 December 2024 Receive via e-mail

PSMA Imaging and Response Evaluation for Prostate CancerSent on 11 December 2024 Receive via e-mail

Treatments Targeting Resistance and Unlocking Immune Responses in Advanced Prostate Cancer Sent on 10 December 2024 Receive via e-mail

Clinical Progression of Prostate Cancer from Active Surveillance is Predicted by Decipher® Genomic Classifier Score on Index Biopsy & More from 2024 SUO Sent on 09 December 2024 Receive via e-mail

SUO 2024: Setting the Stage: Our Current Options for NMIBCSent on 06 December 2024 Receive via e-mail

SUO 2024 Highlights: Advances in RCC, Testicular Cancer, NMIBC, and Emerging Therapies Sent on 06 December 2024 Receive via e-mail

CG Oncology Announces Bond-003 Topline ResultsSent on 05 December 2024 Receive via e-mail

Society of Urologic Oncology (SUO) 2024: Exploring Advanced Disease, Adjuvant Therapy, and the Impact of Smoking CessationSent on 05 December 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 04 December 2024 Receive via e-mail

Society of Urologic Oncology (SUO) 2024 Advancements in Bladder Cancer TreatmentSent on 04 December 2024 Receive via e-mail

Novel Treatment Approaches in Metastatic Castration-resistant Prostate CancerSent on 04 December 2024 Receive via e-mail

Reducing Bladder Cancer Recurrence: The Role of Improved Detection in Bladder CancerSent on 30 November 2024 Receive via e-mail

Genomic Insights in Metastatic Hormone-Sensitive Prostate Cancer Sent on 29 November 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 27 November 2024 Receive via e-mail

In Gratitude and Appreciation, A Message From UroToday!Sent on 27 November 2024 Receive via e-mail

New Horizons in the Treatment of Bladder CancerSent on 26 November 2024 Receive via e-mail

Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer TreatmentsSent on 25 November 2024 Receive via e-mail

Emerging Technologies to Advance Urologic Care in 2025 - LUGPA 2024 Annual Meeting PresentationsSent on 23 November 2024 Receive via e-mail

Integrating New Technologies into Practice Management: LUGPA 2024 Annual EducationSent on 22 November 2024 Receive via e-mail

Precision Medicine at the Forefront of mCRPC TherapySent on 21 November 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 20 November 2024 Receive via e-mail

Innovative Therapies in GU CancersSent on 20 November 2024 Receive via e-mail

Variant Histology Bladder Cancer Challenges and Future DirectionsSent on 18 November 2024 Receive via e-mail

Advances in Staging and Personalized Radiation TherapySent on 15 November 2024 Receive via e-mail

Risk Assessment and Treatment Intensification in Advanced Prostate CancerSent on 14 November 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 13 November 2024 Receive via e-mail

Reducing Financial Burdens and Advancing Personalized Prostate Cancer Care for VeteransSent on 13 November 2024 Receive via e-mail

Occupational and Environmental Risk Factors in Bladder CancerSent on 12 November 2024 Receive via e-mail

The Contemporary Role of Immunotherapy in Bladder Cancer Sent on 11 November 2024 Receive via e-mail

Breakthrough Data in the Treatment of Advanced Prostate Cancer Sent on 08 November 2024 Receive via e-mail

Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global ImplementationSent on 07 November 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 06 November 2024 Receive via e-mail

Targeted Treatment with Radioligand Therapy in Advanced Prostate CancerSent on 06 November 2024 Receive via e-mail

Advanced Prostate Cancer - Understanding Out-of-Pocket Medication CostsSent on 05 November 2024 Receive via e-mail

Machine Learning Predicts Financial Toxicity in Stage IIA Non-Seminoma TreatmentsSent on 04 November 2024 Receive via e-mail

BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence from South Central Section AUASent on 02 November 2024 Receive via e-mail

South Central Section American Urological Association on Emerging Treatments for NMIBC and Ablative Treatments for Renal Cell CarcinomaSent on 01 November 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 31 October 2024 Receive via e-mail

South Central Section American Urological Association (AUA): Insights in Prostate Cancer Treatment Sent on 31 October 2024 Receive via e-mail

Bladder Preservation Strategies - A Modern Choice for PatientsSent on 29 October 2024 Receive via e-mail

Strategies for Diagnosis and Treatment of Metastatic Prostate CancerSent on 25 October 2024 Receive via e-mail

Evaluating Combination Treatments in Various Stages of Prostate Cancer Sent on 24 October 2024 Receive via e-mail

UroAlert - GU Oncology WeeklySent on 24 October 2024 Receive via e-mail

Harnessing Artificial Intelligence in Bladder Cancer - Digital Tools for Enhanced Diagnosis and Treatment Sent on 23 October 2024 Receive via e-mail

Page of 49

Display #
Results 1 - 50 out of 2421

Send the selected Newsletters to...

Name
E-mail

About UroToday
Journals
Calendar
Editorial and Advertising Guidelines
Editors and Contributors
FAQs
Privacy Policy
Terms of Use

Follow UroToday

COPYRIGHT © 2002 - 2024 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

Email

Password

Forgot Password?
Sign Up Free